Evidence map›Paper›PMID 28947468›Full record

Trial reportBMJ open2017

Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial.

Shao J Zhou, Karen Best, Robert Gibson, Andrew McPhee, Lisa Yelland, Julie Quinlivan, Maria Makrides

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Omega-3 fatty acid addition during pregnancy.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shao J ZhouHealthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, Australia.
Karen BestHealthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, Australia.
Robert GibsonSchool of Agriculture, Food and Wine, The University of Adelaide, Adelaide, South Australia, Australia.
Andrew McPheeDepartment of Neonatal Services, Women's and Children's Health Network, Adelaide, Australia.
Lisa YellandHealthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, Australia.
Julie QuinlivanInstitute for Health Research, University of Notre Dame Australia, Fremantle, Australia.
Maria MakridesHealthy Mothers, Babies and Children, South Australian Health and Medical Research Institute, Adelaide, Australia.
University of Adelaide · AUSouth Australian Health and Medical Research Institute · AUThe University of Notre Dame Australia · AUWomen's and Children's Health Network · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPreterm birth accounts for more than 85% of all perinatal complications and deaths. Seventy-five per cent of early preterm births (EPTBs) occur spontaneously and without identifiable risk factors. The need for a broadly applicable, effective strategy for primary prevention is paramount. Secondary outcomes from the docosahexaenoic acid (DHA) to Optimise Mother Infant Outcome trial showed that maternal supplementation until delivery with omega-3 (ω-3) long chain polyunsaturated fatty acid (LCPUFA), predominantly as DHA, resulted in a 50% reduction in the incidence of EPTB and an increase in the incidence of post-term induction or post-term prelabour caesarean section due to extended gestation. We aim to determine the effectiveness of supplementing the maternal diet with ω-3 LCPUFA until 34 weeks' gestation on the incidence of EPTB. METHODS AND ANALYSIS: This is a multicentre, parallel group, randomised, blinded and controlled trial. Women less than 20 weeks' gestation with a singleton or multiple pregnancy and able to give informed consent are eligible to participate. Women will be randomised to receive high DHA fish oil capsules or control capsules without DHA. Capsules will be taken from enrolment until 34 weeks' gestation. The primary outcome is the incidence of EPTB, defined as delivery before 34 completed weeks' gestation. Key secondary outcomes include length of gestation, incidence of post-term induction or prelabour caesarean section and spontaneous EPTB. The target sample size is 5540 women (2770 per group), which will provide 85% power to detect an absolute reduction in the incidence of preterm birth of 1.16% (from 2.45% to 1.29%) between the DHA and control group (two sided α=0.05). The primary analysis will be based on the intention-to-treat principle. TRIAL REGISTRATION NUMBER: Australia and New Zealand Clinical Trial Registry Number: 2613001142729; Pre-results.

Indexed as

AdultCase-Control StudiesClinical ProtocolsDietary FatsDietary SupplementsFatty Acids, Omega-3FemaleGestational AgeHumansInfant, NewbornPregnancyPremature BirthDietary FatsFatty Acids, Omega-3maternal dietocosahexaenoic acidomega-3 long chain polyunsaturated fatty acidspregnancypreterm birthpreventive medicine

Identifiers

PMID28947468
PMCPMC5623491
OpenAlexW2759029100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.